This is a Phase 1b multicenter study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 long haulers with pulmonary compromise.~COVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4.
This is a Phase 1b study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 long haulers with pulmonary compromise.